Drug/indication: Uceris for ulcerative colitis
Approval decision date: Oct. 16
Drug/indication: IPX066 for Parkinson's disease
Approval decision date: Oct. 19
Drug/indication: Oral Remodulin for pulmonary arterial hypertension
Approval decision date: Oct. 26
Drug/indication: Lixivaptan for hyponatremia
Approval decision date: Oct. 29
Drug/indication: MDV3100 for prostate cancer
Approval decision date: Nov. 21 Exelixis (EXEL)
Drug/indication: Cabozantinib for medullary thyroid cancer
Approval decision date: Nov. 29
Alexza Pharmaceuticals (ALXA)
Drug/indication: Adasuve for agitation due to schizophrenia
Approval decision date: Dec. 21
This is Alexza's third attempt at Adasuve approval. Aegerion Pharmaceuticals (AEGR)
Drug/indication: Lomitapide for dyslipidemia/hypercholesterolemia
Approval decision date: Dec. 28 Biogen Idec (BIIB)
Drug/indication: BG-12 for multiple sclerosis
Approval decision date: Dec. 28
BG-12 would be Biogen's first pill for multiple sclerosis. NuPathe (PATH)
Drug/indication: Zelrix for migraine
Approval decision date: Jan. 16, 2013
This is NuPathe's second attempt at Zelrix approval. Sanofi and Isis Pharmaceuticals (ISIS)
Drug/indication: Kynamro for hypercholesterolemia
Approval decision date: Jan. 29, 2013
Raptor Pharmaceutical (RPTP)
Drug/indication: RP103 for cystinosis
Approval decision date: Jan. 30, 2013. Celgene (CELG)
Drug/indication: Pomalidomide for multiple myeloma
Approval decision date: Feb. 10, 2013. Dynavax (DVAX)
Drug/indication: Heplisav for hepatitis B prevention
Approval decision date: Feb. 24, 2013 Sources: Company reports, TheStreet research, BioMedTracker.com --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV